Status:
COMPLETED
Effects of Lactobacillus Plantarum PS128 in Patients With Tourette's Syndrome
Lead Sponsor:
China Medical University Hospital
Collaborating Sponsors:
Bened Biomedical Co., Ltd.
Conditions:
Tourette's Syndrome
Eligibility:
All Genders
4-18 years
Phase:
NA
Brief Summary
To evaluate whether supplementing with PS128 can improve the symptoms and quality of life related to Tourette's disease in children.
Detailed Description
This is a randomized double-blind healthy control study and the implementation period is after Institutional Review Board (IRB) approval to December 31, 2022. Experimental group: 80 subjects who meet...
Eligibility Criteria
Inclusion
- Age 4-18 years old
- Tourette's disease is diagnosed
- Make sure it is not caused by medication or other diseases
- Cause major interference in social interaction, study or work
- The healthy control group is not diagnosed with Tourette's disease, and is judged by PI
Exclusion
- Have taken antibiotics within a month or are receiving antibiotic treatment
- Used probiotic products in powder, capsule or tablet form within two weeks (except yogurt, yogurt, Yakult and other related foods)
- Patients who have undergone hepatobiliary gastrointestinal surgery (except for colorectal polypectomy and appendectomy)
- Inflammatory bowel disease, such as Crohn's disease or ulcerative colitis
- Those with a history of cancer
- Those who are allergic to lactic acid bacteria products
- Those who are not suitable to participate judged by PI
Key Trial Info
Start Date :
November 29 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
121 Patients enrolled
Trial Details
Trial ID
NCT04805385
Start Date
November 29 2021
End Date
December 31 2023
Last Update
June 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China Medical University Hospital
Taichung, Taiwan, 404332